Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib + Defactinib in recurrent low-grade serous ovarian cancer (Japanese patients)
NCT06682572Phase 2Active, not recruiting
- Sponsor
- Verastem Oncology
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avutometinib in Low grade serous ovarian cancer (LGSOC), sponsored by Verastem Oncology. Started Oct 2024; status: active, not recruiting.
02
Drugs
avutometinib
03
Conditions
Low grade serous ovarian cancer (LGSOC)
Beyond the preview
Go deeper on NCT06682572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682572.